OncoSil Medical Limited (ASX:OSL), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer and distal cholangiocarcinoma, has advised that all eight resolutions put to shareholders at its Annual General Meeting held on 18 November 2026 were carried by poll.

Key Points

  • All eight resolutions at the 18 November 2026 Annual General Meeting were carried by poll.
  • The remuneration report was adopted with 99.60% of poll votes cast in favour.
  • Ms Lelde Smits was re-elected as a director with 99.96% of poll votes cast in favour.
  • The 10% placement facility received 97.71% of poll votes in favour, the lowest approval rate among the eight resolutions.
  • Options were approved for issue to CEO Mr Nigel Lange, Dr Thomas Duthy, and Ms Lelde Smits.

Voting Results on Director and Remuneration Resolutions

The adoption of the remuneration report was carried with 16,678,397 votes in favour, representing 99.60% of poll votes cast, against 66,526 votes or 0.40%. The re-election of Ms Lelde Smits as a director was carried with 16,944,518 votes in favour, representing 99.96% of poll votes cast, against 7,457 votes or 0.04%. All resolutions were decided by poll in accordance with ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001.

Approval of Options for Key Personnel

Shareholders approved the issue of options to three individuals. The resolution approving options to CEO and Managing Director Mr Nigel Lange was carried with 16,641,044 votes or 99.43% in favour, against 94,983 votes or 0.57%. The resolution for options to Dr Thomas Duthy was carried with 16,658,170 votes or 99.51% in favour, against 81,857 votes or 0.49%. Options to Ms Lelde Smits were approved with 16,661,410 votes or 99.53% in favour, against 78,617 votes or 0.47%.

Omnibus Plan, Placement Facility and Ratification of Prior Issues

The approval of the Omnibus Plan was carried with 16,656,646 votes or 99.66% in favour, against 57,356 votes or 0.34%. The approval of a 10% placement facility was carried with 16,574,697 votes or 97.71% in favour, against 389,302 votes or 2.29%. The ratification of prior issues of placement shares was carried with 16,901,241 votes or 99.65% in favour, against 60,066 votes or 0.35%. The filing states the announcement was authorised by the Chairman of OncoSil Medical Limited.